Metastatic breast cancer response after Exemestane withdrawal: a case report.

Abstract

A forty-three year old female patient with right sided breast cancer was treated with adjuvant radiotherapy and Tamoxifen. She had a relapse in the right supraclavicular fossa after a disease free period of 12 years. She progressed, after a short period of disease stabilization on Idoxifene followed by a further stable period on Anastrazole. At further disease relapse, she was commenced on Exemestane. After a period of disease stabilization and subsequent disease progression in the right supraclavicular fossa, Exemestane was discontinued. Six weeks later there was a marked regression of the right supraclavicular mass. Withdrawal response to Tamoxifen is well documented. To our knowledge a similar response after Exemestane withdrawal has not been reported in the literature.

• Authors: S A Bhide, D W Rea
• Journal: Breast (Edinburgh, Scotland) (Breast) Vol. 13 Issue 1 Pg. 66-8 (Feb 2004) ISSN: 0960-9776 [Print] Netherlands
• PMID: 14759719 (Publication Type: Case Reports, Journal Article)

Chemical References

• Androstadienes
• Antineoplastic Agents
• Aromatase Inhibitors
• Enzyme Inhibitors
• exemestane

Topics

• Adult
• Androstadienes (administration & dosage, therapeutic use)
• Antineoplastic Agents (administration & dosage, therapeutic use)
• Aromatase Inhibitors
• Breast Neoplasms (drug therapy, pathology)
• Carcinoma, Ductal, Breast (drug therapy, pathology)
• Enzyme Inhibitors (administration & dosage, therapeutic use)
• Female
• Humans
• Neoplasm Recurrence, Local (drug therapy, pathology)
• Remission, Spontaneous